Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human (tested or 100% immunogen sequence identity)
IgG2a Monoclonal [MEM-43]
IHC - Paraffin (5 µg/ml)
IHC - Frozen
Specificity and Use
Immunohistochemistry: LS-B2106 was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary antibody, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphatase-streptavidin and chromogen. The stained slides were evaluated by a pathologist to confirm staining specificity. The optimal working concentration for LS-B2106 was determined to be 5 ug/ml. Flow Cytometry: Use 10 ul of the suggested working dilution to label 10^6 cells in 100ul. Immunohistochemistry: This product requires antigen retrieval using heat treatment methods prior to staining of paraffin sections. Sodium citrate buffer pH6.0 is recommended for this purpose. Histology Positive Control Tissue: Tonsil.
PBS, 0.09% sodium azide.
+4°C or -20°C, Avoid repeated freezing and thawing.
CD59 is a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation.